MedTrace Logo

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-04-20

No results posted yet for this study

Summary

The use of vaginal estrogen cream in conjunction with Toviaz will be more effective than the use of Toviaz alone for the treatment of overactive bladder.

Conditions

Interventions

DRUG

Toviaz

Toviaz 4mg daily

DRUG

Premarin

Premarin cream 1 g per vagina twice weekly

DRUG

Placebo cream

Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Eric Hurtado, MD · Cleveland Clinic Florida

  • Alexandriah Alas, MD · Cleveland Clinic Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2018-04-30
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613170 on ClinicalTrials.gov